Experienced DMPK scientist with extensive knowledge of drug metabolism pathways, drug metabolism assays (e.g., CYP450 inhibition), metabolite identification, and radiolabeled mass balance studies. Working knowledge of pharmacokinetics (Win-nonlin software) and human dose projection calculations.Management experience with direct report scientists (Ph.D. and B.A. level) and on two occasions I was in charge of the entire DMPK group.Project team representation for a number of projects in the cancer and immunology. Experience writing the DMPK section of the Investigator's Brochure, IND's and NDA's. For Rigel's SYK inhibitor Fostamatinib I answered DMPK questions that were raised by the reviewers in Europe and Canada to help get the drug approved in these countries. In addition, I worked with our Japanese colleagues at Kissei Pharmaceutical company to help get fostamatinib approved in Japan,